Physician profile
Douglas Thomas Johnston
NPI 1124048079
$329,452.84
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $153K · 2020: $77K · 2021: $99K · 2022: $448 · 2023: $20.88.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $20.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $20.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $107,539.75 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $70,725.78 | 2020-2022 | |
| Pharming Healthcare, INC. | $47,727.62 | 2019-2022 | |
| Csl Behring | $32,016.68 | 2019-2022 | |
| Biocryst Pharmaceuticals, INC. | $28,663.71 | 2019-2021 | |
| Biocryst US Sales Co., LLC | $12,423.60 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $11,887.50 | 2020 | |
| Astrazeneca Pharmaceuticals Lp | $7,342.76 | 2019-2022 | |
| Pfizer INC. | $4,691.34 | 2019-2021 | |
| Genentech USA, INC. | $2,306.13 | 2019-2021 | |
| Adare Pharmaceuticals, INC. | $1,457.84 | 2020 | |
| Glaxosmithkline, LLC. | $689.88 | 2019-2022 | |
| Kaleo, INC. | $419.36 | 2019-2022 | |
| Genzyme Corporation | $312.84 | 2019-2022 | |
| Covis Pharma Gmbh | $246.12 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $202.17 | 2019 | |
| Optinose US, INC. | $182.89 | 2020-2021 | |
| Grifols USA, LLC | $111.84 | 2021-2022 | |
| Alk-Abello, INC | $106.71 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $61.31 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $58.16 | 2019 | |
| Amgen INC. | $54.81 | 2021-2022 | |
| Incyte Corporation | $39.99 | 2021 | |
| Octapharma USA, INC. | $36.13 | 2022 | |
| Phadia US INC. | $32.84 | 2020 | |
| Gilead Sciences, INC. | $22.88 | 2019 | |
| Horizon Therapeutics Plc | $21.15 | 2020 | |
| Atricure, INC. | $20.88 | 2023 | |
| Circassia INC. | $18.91 | 2019 | |
| Mylan Specialty L.P. | $16.00 | 2019 | |
| Neos Therapeutics, Lp | $15.26 | 2021 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Johnston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.